Displaying 1 - 20 of 311
FTC Submits Comment Supporting Proposed USPTO Terminal Disclaimer Rule
FTC Releases Interim Staff Report on Prescription Drug Middlemen
FTC Submits Comment Supporting Proposed USPTO Rule
FTC Expands Patent Listing Challenges, Targeting More Than 300 Junk Listings for Diabetes, Weight Loss, Asthma and COPD Drugs
Caremark/ESI/Optum
FTC, HHS Extend Public Comment Period on Generic Drug Shortages and Competition Request for Information
FTC, HHS Seek Public Comment on Generic Drug Shortages and Competition Amongst Powerful Middlemen
FTC Submits Comment on March-In Rights to Promote Efforts to Lower Drug Prices
Statement on Second Circuit Order Upholding “Pharma Bro” Martin Shkreli’s Lifetime Ban
Vyera Pharmaceuticals, LLC
The Federal Trade Commission and a group of seven state enforcers filed a complaint in federal district court against Vyera Pharmaceuticals, LLC, alleging an elaborate anticompetitive scheme to preserve a monopoly for the life-saving drug, Daraprim. The Commission vote to issue the complaint was 5-0. The complaint was filed on Jan. 27, 2020, in the U.S. District Court for the Southern District of New York. In a Jan. 14, 2022 ruling, U.S. District Court Judge Denise Cote found Shkreli’s conduct “egregious, deliberate, repetitive, long-running, and ultimately dangerous.” Judge Cote banned Shkreli for life from the pharmaceutical industry.
On January 23, 2024, the U.S. Court of Appeals for the Second Circuit affirmed the U.S. District Court for the Southern District of New York’s ruling.
Statement of Chair Lina M. Khan Joined by Commissioner Rebecca Kelly Slaughter In the Matter of Sanofi/Maze Therapeutics
Sanofi/Maze Therapeutics, Inc., In the Matter of
On December 13, 2023, the FTC moved to dismiss its case challenging the transaction following Sanofi’s decision to terminate its transaction with Maze Therapeutics Inc.
FTC Approves Final Order Settling Horizon Therapeutics Acquisition Challenge
Amgen, Inc. and Horizon Therapeutics plc, In the Matter of
In August 2023, the FTC reached a proposed consent order with Amgen Inc. to address the potential competitive harm that would result from Amgen’s $27.8 billion acquisition of Horizon Therapeutics plc. As part of a nationwide settlement of their challenge to the acquisition, the FTC and attorneys general from six states – California, Illinois, Minnesota, New York, Washington, and Wisconsin – also dismissed the related federal court preliminary injunction action, allowing the transaction to proceed, with the conditions imposed by the order. In December 2023, the FTC finalized the consent order with Amgen Inc. and appointed a monitor.